Biopsy Assay Articles & Analysis
9 news found
With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives and insight across a broad spectrum of topics, from strategic development to operational expertise and go-to- market potential for our products” said Pr. ...
The assay also demonstrated 20% sensitivity for advanced adenomas (95% CI; 11% - 32%) and 92% specificity (true negative rate) in normal cases. ...
FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ ...
FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ ...
In December 2019, Palmetto GBA expanded LCD of the Guardant360® assay, making it the first liquid biopsy to be broadly covered for use across the vast majority of advanced solid tumor cancers. ...
Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ ...
Forward-Looking Statement This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ ...
Exosome Diagnostics is the world leader in developing exosomal liquid biopsy-based diagnostic assays. The EPI test is a non-invasive, urine-based genomic test that helps inform the prostate biopsy decision. This liquid biopsy test continues to expand its presence and usage among urologists and primary care physicians in the US. ...
Data from that clinical trial were presented at the 2019 European Society for Medical Oncology (ESMO) Congress. The Oncomine Precision Assay is a next-generation sequencing (NGS) assay that is used to detect key biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue or liquid biopsy specimen. The assay contains more than ...